Matthew Caufield Analyst PerformanceDirector, Senior Biotechnology Equity Research Analyst at HC WainwrightMatthew Caufield is a stock analyst at HC Wainwright focused in the healthcare sector, covering 25 publicly traded companies. Over the past year, Matthew Caufield has issued 61 stock ratings, including buy and hold recommendations. While full access to Matthew Caufield's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Matthew Caufield's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access to unlock analyst rankings MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings170 Last 4 YearsBuy Recommendations88.76% 150 Buy RatingsCompanies Covered25 Unique Companies Ratings Distribution169RatingsDistribution of strong buy, buy, hold, and sell ratings by Matthew Caufield.RatingPercentageCount Strong Buy0.0%0 ratings Buy88.8%150 ratings Hold11.2%19 ratings Sell0.0%0 ratingsOut of 169 total stock ratings issued by Matthew Caufield at HC Wainwright, the majority (88.8%) have been Buy recommendations, followed by 11.2% Hold.Best & Worst CallsBest Call0000.0%KODNov 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%LYRAOct 2023Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ96.0% of companies on NASDAQ24 companiesOTCMKTS4.0% of companies on OTCMKTS1 companyMatthew Caufield, an analyst at HC Wainwright, currently covers 25 companies listed on NASDAQ and OTCMKTS, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare24 companies96.0%Finance1 company4.0%Matthew Caufield of HC Wainwright specializes in stock coverage within the Healthcare sector, with additional focus on Finance companies.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY15 companies60.0%PHARMACEUTICALS9 companies36.0%FINANCIAL SERVICES1 company4.0% About Matthew CaufieldMatthew Caufield is a Vice President of Equity Research at H.C. Wainwright, having joined the firm in 2018. Mr. Caufield’s research focuses on small and mid-cap biotechnology companies including innovations in the ophthalmology and gastrointestinal industries. Prior to joining H.C. Wainwright, Mr. Caufield was an Equity Research Associate at Piper Sandler & Co. assisting in the coverage of small and mid-cap biotechnology companies. Mr. Caufield previously worked as a Senior Wealth Strategy Associate in Private Wealth Management at UBS, and as an Investment Service Associate at JPMorgan Chase & Co. Mr. Caufield is a published scientist, and his educational background includes an MBA from the S.C. Johnson Graduate School of Management at Cornell University, a M.S. in Neurobiology from Northwestern University, and a B.S. in Neuroscience from Colgate University.Follow on LinkedIn Matthew Caufield's Ratings History at HC Wainwright Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter More filters Fewer filters Done 0 Results Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsLQDALiquidia11/13/2026Initiated Coverage$58.12$76.00Buy$0.0000.00% ROISVRASavara11/12/2026Initiated Coverage$4.99$10.00Buy$0.0000.00% ROIIRDOpus Genetics11/11/2026Boost Price Target$4.23$14.00Buy$0.0000.00% ROIUPBUpstream Bio11/11/2026Lower Price Target$3.38$18.00Buy$0.0000.00% ROIUTHRUnited Therapeutics11/9/2026Initiated Coverage$562.02$660.00Buy$0.0000.00% ROITARSTarsus Pharmaceuticals11/4/2026Boost Price Target$72.64$106.00Buy$0.0000.00% ROIPHATPhathom Pharmaceuticals10/30/2026Reiterated Rating$6.22Buy$0.0000.00% ROILENZLENZ Therapeutics10/30/2026Lower Price Target$3.49$16.00Buy$0.0000.00% ROIFDMT4D Molecular Therapeutics10/22/2026Reiterated Rating$12.62$36.00Buy$0.0000.00% ROIZBIOZenas BioPharma10/13/2026Reiterated Rating$26.40$44.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. KODKodiak Sciences10/12/2026Boost Price Target$99.87$126.00Buy$0.0000.00% ROIMLYSMineralys Therapeutics10/12/2026Reiterated Rating$23.37$56.00Buy$0.0000.00% ROIZBIOZenas BioPharma9/30/2026Reiterated Rating$26.76$44.00Buy$0.0000.00% ROIALDXAldeyra Therapeutics9/30/2026Reiterated Rating$1.32$2.00Neutral$0.0000.00% ROIKODKodiak Sciences9/28/2026Boost Price Target$87.03$96.00Buy$0.0000.00% ROISRZNSurrozen9/25/2026Reiterated Rating$33.68$54.00Buy$0.0000.00% ROIKODKodiak Sciences9/17/2026Reiterated Rating$32.77$58.00Buy$0.0000.00% ROIIMUXImmunic9/10/2026Reiterated Rating$12.19$22.00Buy$0.0000.00% ROIIRDOpus Genetics9/9/2026Reiterated Rating$5.47$8.00Buy$0.0000.00% ROIUPBUpstream Bio9/2/2026Reiterated Rating$6.55$36.00Buy$0.0000.00% ROIKODKodiak Sciences8/17/2026Reiterated Rating$41.35$58.00Buy$0.0000.00% ROIDMACDiaMedica Therapeutics8/11/2026Reiterated Rating$6.87$12.00Buy$0.0000.00% ROISRZNSurrozen8/10/2026Reiterated Rating$25.62$44.00Buy$0.0000.00% ROIAKBAAkebia Therapeutics8/6/2026Reiterated Rating$1.29Buy$0.0000.00% ROIFBLGFibroBiologics8/4/2026Reiterated Rating$0.79$6.00Buy$0.0000.00% ROIPHATPhathom Pharmaceuticals7/31/2026Reiterated Rating$9.03$26.00Buy$0.0000.00% ROIFDMT4D Molecular Therapeutics7/20/2026Reiterated Rating$10.99$36.00Buy$0.0000.00% ROITARSTarsus Pharmaceuticals7/9/2026Reiterated Rating$67.73$88.00Buy$0.0000.00% ROILENZLENZ Therapeutics7/7/2026Reiterated Rating$5.60Buy$0.0000.00% ROIAKBAAkebia Therapeutics7/1/2026Reiterated Rating$1.14$6.00Buy$0.0000.00% ROIPHATPhathom Pharmaceuticals6/17/2026Reiterated Rating$10.43$26.00Buy$0.0000.00% ROIIRDOpus Genetics6/17/2026Reiterated Rating$3.90$8.00Buy$0.0000.00% ROIZBIOZenas BioPharma6/3/2026Reiterated Rating$17.13Buy$0.0000.00% ROIUPBUpstream Bio6/3/2026Initiated Coverage$7.25$36.00Buy$0.0000.00% ROIUPBUpstream Bio6/3/2026Initiated Coverage$7.63$36.00Buy$0.0000.00% ROIMLYSMineralys Therapeutics6/1/2026Reiterated Rating$31.50Buy$0.0000.00% ROIZBIOZenas BioPharma5/15/2026Reiterated Rating$18.90$44.00Buy$0.0000.00% ROILENZLENZ Therapeutics5/12/2026Lower Price Target$9.99$38.00Buy$0.0000.00% ROISRZNSurrozen5/7/2026Reiterated Rating$34.13$44.00Buy$0.0000.00% ROITARSTarsus Pharmaceuticals5/4/2026Reiterated Rating$63.62$88.00Buy$0.0000.00% ROIWhat the hell is going on? (Ad)Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.Watch Porter Stansberry's full broadcast on the coming dollar reset nowIMUXImmunic4/30/2026Reiterated Rating$10.03$22.00Buy$0.0000.00% ROILENZLENZ Therapeutics4/21/2026Lower Price Target$10.13$48.00Buy$0.0000.00% ROIFBLGFibroBiologics4/16/2026Reiterated Rating$1.51$8.00Buy$0.0000.00% ROIKODKodiak Sciences3/27/2026Reiterated Rating$39.76$58.00Buy$0.0000.00% ROISRZNSurrozen3/24/2026Reiterated Rating$25.24$36.00Buy$0.0000.00% ROIFDMT4D Molecular Therapeutics3/20/2026Reiterated Rating$8.98$36.00Buy$0.0000.00% ROIALDXAldeyra Therapeutics3/18/2026Downgrade$1.24$2.00Neutral$0.0000.00% ROIZBIOZenas BioPharma3/17/2026Reiterated Rating$23.23$44.00Buy$0.0000.00% ROIMLYSMineralys Therapeutics3/10/2026Set Price Target$27.10$56.00Buy$0.0000.00% ROIIMUXImmunic3/2/2026Lower Price Target$10.20$50.00Buy$0.0000.00% ROIFBLGFibroBiologics2/26/2026Lower Price Target$5.27$80.00Buy$0.0000.00% ROIARDXArdelyx2/20/2026Boost Price Target$6.74$18.00Buy$0.0000.00% ROIZBIOZenas BioPharma2/10/2026Reiterated Rating$22.48$44.00Buy$0.0000.00% ROIKODKodiak Sciences2/10/2026Reiterated Rating$24.30$38.00Buy$0.0000.00% ROIIMUXImmunic2/9/2026Reiterated Rating$6.20$80.00Buy$0.0000.00% ROIAKBAAkebia Therapeutics2/6/2026Reiterated Rating$1.38$6.00Buy$0.0000.00% ROIKODKodiak Sciences1/22/2026Boost Price Target$26.71$38.00Buy$0.0000.00% ROIFBLGFibroBiologics1/2/2026Reiterated Rating$4.50$100.00Buy$0.0000.00% ROIZBIOZenas BioPharma12/16/2025Reiterated Rating$32.59Buy$0.0000.00% ROILENZLENZ Therapeutics12/15/2025Reiterated Rating$18.14Buy$0.0000.00% ROIAKBAAkebia Therapeutics12/2/2025Reiterated Rating$1.51$6.00Buy$0.0000.00% ROIADVMAdverum Biotechnologies11/17/2025Reiterated Rating$4.29$5.00Neutral$0.0000.00% ROIKODKodiak Sciences11/17/2025Boost Price Target$19.51$26.00Buy$000.0000.00% ROIIMUXImmunic11/14/2025Lower Price Target$7.13$80.00Buy$0.0000.00% ROIMLYSMineralys Therapeutics11/12/2025Boost Price Target$47.11$56.00Buy$00.0000.00% ROIKODKodiak Sciences11/11/2025Upgrade$18.49$24.00Buy$000.0000.00% ROIPHATPhathom Pharmaceuticals10/31/2025Boost Price Target$13.31$26.00Buy$0.0000.00% ROIMLYSMineralys Therapeutics10/30/2025Boost Price Target$40.14$52.00Buy$00.0000.00% ROIAKBAAkebia Therapeutics10/30/2025Lower Price Target$2.10$6.00Buy$0.0000.00% ROIZBIOZenas BioPharma10/28/2025Boost Price Target$31.80$44.00Buy$00.0000.00% ROILENZLENZ Therapeutics10/27/2025Reiterated Rating$31.86$56.00Buy$0.0000.00% ROITARSTarsus Pharmaceuticals10/20/2025Boost Price Target$72.93$88.00Neutral$00.0000.00% ROITARSTarsus Pharmaceuticals10/20/2025Reiterated Rating$72.93$88.00Buy$00.0000.00% ROIZBIOZenas BioPharma10/9/2025Reiterated Rating$25.90$30.00Buy$00.0000.00% ROIIMUXImmunic9/26/2025Reiterated Rating$8.98$100.00Buy$0.0000.00% ROIADVMAdverum Biotechnologies9/23/2025Reiterated Rating$3.46$30.00Buy$0.0000.00% ROIFBLGFibroBiologics9/12/2025Reiterated Rating$11.30$200.00Buy$0.0000.00% ROIMLYSMineralys Therapeutics9/8/2025Reiterated Rating$34.80$42.00Buy$00.0000.00% ROIKODKodiak Sciences8/18/2025Boost Price Target$10.57$5.00Neutral$00.0000.00% ROIDMACDiaMedica Therapeutics8/15/2025Reiterated Rating$6.01$12.00Buy$0.0000.00% ROILYRALyra Therapeutics8/14/2025Reiterated Rating$7.29Neutral$0.0000.00% ROIMLYSMineralys Therapeutics8/13/2025Reiterated Rating$13.51$42.00Buy$00.0000.00% ROIFBLGFibroBiologics8/5/2025Reiterated Rating$12.17$240.00Buy$0.0000.00% ROILENZLENZ Therapeutics7/28/2025Boost Price Target$31.62$48.00Buy$0.0000.00% ROIDMACDiaMedica Therapeutics7/18/2025Boost Price Target$3.93$12.00Buy$0.0000.00% ROIIRDOpus Genetics6/27/2025Reiterated Rating$1.02$8.00Buy$0.0000.00% ROIARDXArdelyx6/18/2025Initiated Coverage$3.55$10.00Buy$0.0000.00% ROIMLYSMineralys Therapeutics6/17/2025Reiterated Rating$13.72$42.00Buy$00.0000.00% ROIPHATPhathom Pharmaceuticals6/9/2025Reiterated Rating$8.92$20.00Buy$00.0000.00% ROIAKBAAkebia Therapeutics6/4/2025Initiated Coverage$3.42$8.00Buy$0.0000.00% ROIDrop these 5 stocks before the market opens tomorrow! (Ad)The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.See the five stocks Weiss Ratings analysts are watching closely now.DMACDiaMedica Therapeutics5/29/2025Reiterated Rating$4.16$10.00Buy$0.0000.00% ROIUBXUNITY Biotechnology5/27/2025Reiterated Rating$0.78$2.00Neutral$0.0000.00% ROITARSTarsus Pharmaceuticals5/27/2025Upgrade$42.98$72.00Buy$00.0000.00% ROIALDXAldeyra Therapeutics5/19/2025Reiterated Rating$2.16$10.00Buy$0.0000.00% ROIZBIOZenas BioPharma5/16/2025Reiterated Rating$9.74$30.00Buy$00.0000.00% ROIADVMAdverum Biotechnologies5/15/2025Reiterated Rating$2.06$30.00Buy$0.0000.00% ROIMLYSMineralys Therapeutics5/13/2025Reiterated Rating$15.01$42.00Buy$00.0000.00% ROISRZNSurrozen5/12/2025Reiterated Rating$8.35$32.00Buy$00.0000.00% ROILENZLENZ Therapeutics5/8/2025Reiterated Rating$25.34$38.00Buy$0.0000.00% ROIPHATPhathom Pharmaceuticals5/2/2025Lower Price Target$3.36$20.00Buy$00.0000.00% ROIIMUXImmunic5/1/2025Reiterated Rating$9.90$100.00Buy$0.0000.00% ROIUBXUNITY Biotechnology4/23/2025Reiterated Rating$0.98$4.00Buy$0.0000.00% ROILENZLENZ Therapeutics4/16/2025Reiterated Rating$23.89$38.00Buy$0.0000.00% ROIADVMAdverum Biotechnologies4/16/2025Reiterated Rating$3.23$30.00Buy$0.0000.00% ROIIMUXImmunic4/15/2025Reiterated Rating$9.18$100.00Buy$00.0000.00% ROIALDXAldeyra Therapeutics4/4/2025Reiterated Rating$1.42$10.00Buy$0.0000.00% ROIMLYSMineralys Therapeutics4/2/2025Boost Price Target$13.84$42.00Buy$00.0000.00% ROISRZNSurrozen4/2/2025Reiterated Rating$11.12$32.00Buy$00.0000.00% ROIFBLGFibroBiologics4/1/2025Reiterated Rating$18.00$240.00Buy$0.0000.00% ROIIRDOpus Genetics4/1/2025Reiterated Rating$0.98$8.00Buy$0.0000.00% ROIKODKodiak Sciences3/31/2025Reiterated Rating$2.91$3.00Neutral$00.0000.00% ROIOPTOpthea3/25/2025Downgrade$3.41$2.00Neutral$0.0000.00% ROIUBXUNITY Biotechnology3/24/2025Lower Price Target$1.20$4.00Buy$0.0000.00% ROIHYPDHyperion DeFi3/21/2025Reiterated Rating$1.44$2.00Neutral$0.0000.00% ROIDMACDiaMedica Therapeutics3/19/2025Boost Price Target$5.21$10.00Buy$0.0000.00% ROILYRALyra Therapeutics3/14/2025Reiterated Rating$8.75$100.00Neutral$0.0000.00% ROIUBXUNITY Biotechnology3/10/2025Reiterated Rating$1.68$8.00Buy$0.0000.00% ROIMLYSMineralys Therapeutics3/10/2025Reiterated Rating$17.53$30.00Buy$00.0000.00% ROIPHATPhathom Pharmaceuticals3/7/2025Reiterated Rating$5.90$28.00Buy$00.0000.00% ROIALDXAldeyra Therapeutics3/3/2025Reiterated Rating$5.11$10.00Buy$0.0000.00% ROIFDMT4D Molecular Therapeutics3/3/2025Reiterated Rating$4.53$36.00Buy$0.0000.00% ROIOPTOpthea2/28/2025Reiterated Rating$4.60$12.00Buy$0.0000.00% ROIIMUXImmunic2/21/2025Reiterated Rating$11.80$100.00Buy$0.0000.00% ROIIRDOpus Genetics2/19/2025Reiterated Rating$1.10$8.00Buy$0.0000.00% ROIMLYSMineralys Therapeutics2/13/2025Reiterated Rating$10.63$30.00Buy$00.0000.00% ROIFBLGFibroBiologics2/13/2025Reiterated Rating$34.60$240.00Buy$0.0000.00% ROIFDMT4D Molecular Therapeutics2/10/2025Reiterated Rating$5.97$36.00Buy$0.0000.00% ROIHYPDHyperion DeFi2/6/2025Reiterated Rating$2.38$2.00Neutral$0.0000.00% ROISRZNSurrozen1/30/2025Initiated Coverage$11.25$32.00Buy$00.0000.00% ROIOPTOpthea1/29/2025Reiterated Rating$5.00$12.00Buy$0.0000.00% ROIFDMT4D Molecular Therapeutics1/13/2025Reiterated Rating$5.52$36.00Buy$0.0000.00% ROIIRDOpus Genetics12/12/2024Reiterated Rating$1.20$8.00Buy$0.0000.00% ROIIMUXImmunic11/25/2024Initiated Coverage$11.00$100.00Buy$0.0000.00% ROIHYPDHyperion DeFi11/18/2024Downgrade$8.15$160.00Neutral$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche BankBMO Capital Markets Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.